Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Herbal granules take on a stomach condition that raises cancer risk

NCT ID NCT05209633

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 27, 2026 · Last updated Jul 28, 2026 · Updated 1 time

Summary

This trial tests whether Dendrobii granules, a traditional Chinese herbal remedy, can improve chronic atrophic gastritis — a condition where the stomach lining thins and raises the risk of stomach cancer. Twenty adults with the condition will receive either the granules or a placebo for 18 weeks. The goal is to see if the treatment can reverse precancerous changes in the stomach lining.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Dendrobii granules (a traditional Chinese medicine preparation)
What this could lead to
If effective, Dendrobii granules could offer a new treatment option for chronic atrophic gastritis and potentially reduce the risk of progression to gastric cancer.
What could go wrong
This is a small, early-phase trial with only 20 participants, so results may not apply broadly. The treatment is based on traditional Chinese medicine and lacks large-scale evidence.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

20 people

The number who actually took part.

Started

Nov 2022

Finished

Nov 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Fulfill the diagnosis of chronic atrophic gastritis; * TCM syndrome differentiation is deficiency of both qi and yin; * Aged between 18 and 65 years old, regardless of gender; * Volunteer to participate in this clinical trial and sign an informed consent form. Exclusion Criteria: * Patients with peptic ulcer, acid reflux, etc. who need PPI treatment; * Patients with high-grade intraepithelial neoplasia of gastric mucosa or suspected malignant transformation in pathological diagnosis; * Those who have received anti-HP treatment and related treatments in the past two weeks; * Diabetic patients; * Patients with severe heart, liver, kidney, lung, blood system diseases, abnormal renal function Cr test with clinical significance, and liver function ALT ≥ 1.5 times the upper limit of the normal reference value; * People with allergies or a history of allergies to multiple drugs (two or more or the known ingredients in the drug); * Those planning to become pregnant, pregnant or breast-feeding; * Patients with mental illness; * Those who have participated in other drug clinical trials within the past 3 months; * The investigator believes that it is not suitable to participate in this clinical trial.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Atrophic gastritis are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic atrophic gastritis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Atrophic gastritis

Contacts and locations

Locations

  • The Chinese University of Hong Kong

    Hong Kong, Hong Kong

More trials for these conditions

Other studies related to the condition(s) this trial covers.